Hydrofluoroalkane mandate in effect January 1, 2009: Switch from chlorofluorocarbon- to hydrofluoroalkane-propelled inhalers requires active transition.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Peters S;Peters S
  • Source:
    Clinical cornerstone [Clin Cornerstone] 2009; Vol. 9 (3), pp. 50-3.
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Excerpta Medica Country of Publication: United States NLM ID: 9816002 Publication Model: Print Cited Medium: Internet ISSN: 1873-4480 (Electronic) Linking ISSN: 18734480 NLM ISO Abbreviation: Clin Cornerstone Subsets: MEDLINE
    • Publication Information:
      Original Publication: Belle Mead, N.J. : Excerpta Medica, c1998-
    • Subject Terms:
    • Abstract:
      The manufacture, sale, and distribution of chlorofluorocarbon-propelled albuterol metered-dose inhalers ceased as of December 31, 2008. Clinicians should actively transition patients to currently available hydrofluoroalkane-propelled devices, providing concise education and instruction for using the newer devices.
    • Accession Number:
      0 (Aerosol Propellants)
      0 (Chlorofluorocarbons)
      0 (Hydrocarbons, Fluorinated)
      R40P36GDK6 (apaflurane)
    • Publication Date:
      Date Created: 20090929 Date Completed: 20091222 Latest Revision: 20191111
    • Publication Date:
      20240829
    • Accession Number:
      10.1016/s1098-3597(09)80013-6
    • Accession Number:
      19781516